Market Research Logo

Neuroblastoma - Pipeline Review, H1 2015

Neuroblastoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Neuroblastoma - Pipeline Review, H1 2015’, provides an overview of the Neuroblastoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neuroblastoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Neuroblastoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Neuroblastoma Overview
Therapeutics Development
Pipeline Products for Neuroblastoma - Overview
Pipeline Products for Neuroblastoma - Comparative Analysis
Neuroblastoma - Therapeutics under Development by Companies
Neuroblastoma - Therapeutics under Investigation by Universities/Institutes
Neuroblastoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Neuroblastoma - Products under Development by Companies
Neuroblastoma - Products under Investigation by Universities/Institutes
Neuroblastoma - Companies Involved in Therapeutics Development
Ability Pharma, SL
Acetylon Pharmaceuticals, Inc.
Advanced Accelerator Applications SA
Aeterna Zentaris Inc.
Ampio Pharmaceuticals, Inc.
APEIRON Biologics AG
Aptose Biosciences Inc.
AstraZeneca Plc
Bellicum Pharmaceuticals, Inc.
Bexion Pharmaceuticals, LLC.
BioLineRx, Ltd.
Bionucleon Srl
Cebiotex, S.L.
Celgene Corporation
Chugai Pharmaceutical Co., Ltd.
Cleveland BioLabs, Inc.
CureFAKtor Pharmaceuticals, LLC
DEKK-TEC, Inc.
Errant Gene Therapeutics, LLC
F. Hoffmann-La Roche Ltd.
Gamida Cell Ltd.
Ignyta, Inc.
Juno Therapeutics Inc.
Lindis Biotech GmbH
MabVax Therapeutics Holdings, Inc.
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Netris Pharma S.A.S.
Novartis AG
Novogen Limited
Pono Pharma
Progenics Pharmaceuticals, Inc.
Recombio S.L
Sareum Holdings Plc
Shionogi & Co., Ltd.
Sutro Biopharma, Inc.
Teva Pharmaceutical Industries Limited
Threshold Pharmaceuticals, Inc.
United Therapeutics Corporation
Neuroblastoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
1-B7 - Drug Profile
31-F9 - Drug Profile
ABTL-0812 - Drug Profile
ACY-957 - Drug Profile
AMXT-1501 + eflornithine hydrochloride - Drug Profile
APN-301 - Drug Profile
APN-311 - Drug Profile
ATM-3507 - Drug Profile
AZ-64 - Drug Profile
BACPT-DP - Drug Profile
bevacizumab - Drug Profile
BL-8040 - Drug Profile
BN-210 - Drug Profile
BPX-701 - Drug Profile
BXQ-350 - Drug Profile
CCT-137690 - Drug Profile
CCT-244747 - Drug Profile
CEB-01 - Drug Profile
Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile
Cell Therapy for Neuroblastoma - Drug Profile
Cell Therapy to Target GD2 for Neuroblastoma - Drug Profile
Cell Therapy to Target GD2 for Neuroblastoma - Drug Profile
celyvir - Drug Profile
CEP-28122 - Drug Profile
CFAKC-4 - Drug Profile
CFAKY-15 - Drug Profile
CG-1521 - Drug Profile
cVE-199 - Drug Profile
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
dinutuximab - Drug Profile
Drugs to Activate Caspase 3 for Oncology - Drug Profile
Edotreotide Labeled Yttrium 90 - Drug Profile
eflornithine hydrochloride - Drug Profile
eh8B6 - Drug Profile
entrectinib - Drug Profile
evofosfamide - Drug Profile
firtecan pegol - Drug Profile
FSEC - Drug Profile
iobenguane sulfate I 131 - Drug Profile
irinotecan sucrosofate liposomal - Drug Profile
JCAR-023 - Drug Profile
Lutathera - Drug Profile
M-606 - Drug Profile
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
Monoclonal Antibody to Target CD3 for Neuroblastoma - Drug Profile
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastom - Drug Profile
Monoclonal Antibody to Target GD2 and CD3 for Neuroblastoma - Drug Profile
Monoclonal Antibody to Target GD2 for Neuroblastoma - Drug Profile
NCE-001 - Drug Profile
NTX-010 - Drug Profile
Oncolytic Virus for Oncology - Drug Profile
P-937 - Drug Profile
paclitaxel albumin bound - Drug Profile
pazopanib hydrochloride - Drug Profile
pembrolizumab - Drug Profile
Peptide to Inhibit HDAC for Neuroblastoma - Drug Profile
perifosine - Drug Profile
racotumomab - Drug Profile
Recombinant Protein to Inhibit HDAC for Neuroblastoma - Drug Profile
ribociclib - Drug Profile
RKS-262 - Drug Profile
RNAi Oligonucleotide for Oncology - Drug Profile
RNAi Oligonucleotides for Neuroblastoma - Drug Profile
RSF-701 - Drug Profile
S-588410 - Drug Profile
SAR-020106 - Drug Profile
SF-1126 - Drug Profile
Small Molecule to Target Netrin-1 Ligand for Oncology - Drug Profile
Small Molecules for Neuroblastoma - Drug Profile
Small Molecules for Neuroblastoma - Drug Profile
Small Molecules to Antagonize ALK for Oncology - Drug Profile
Small Molecules to Inhibit Aurora and ALK Kinase for Oncology - Drug Profile
Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology - Drug Profile
SRX-2523 - Drug Profile
Stem Cells to Activate Natural Killer Cell for Adoptive Cell-Mediated Therapy - Drug Profile
Syrbactins - Drug Profile
TL-118 - Drug Profile
TPI-287 - Drug Profile
TR-100 - Drug Profile
TRBS-07 - Drug Profile
Trilexium - Drug Profile
Vaccine for Neuroblastoma - Drug Profile
Vaccine for Neuroblastoma - Drug Profile
Vaccine for Neuroblastoma - Drug Profile
Vaccine for Neuroblastoma - Drug Profile
Neuroblastoma - Recent Pipeline Updates
Neuroblastoma - Dormant Projects
Neuroblastoma - Discontinued Products
Neuroblastoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Neuroblastoma, H1 2015
Number of Products under Development for Neuroblastoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Neuroblastoma - Pipeline by Ability Pharma, SL, H1 2015
Neuroblastoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015
Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H1 2015
Neuroblastoma - Pipeline by Aeterna Zentaris Inc., H1 2015
Neuroblastoma - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015
Neuroblastoma - Pipeline by APEIRON Biologics AG, H1 2015
Neuroblastoma - Pipeline by Aptose Biosciences Inc., H1 2015
Neuroblastoma - Pipeline by AstraZeneca Plc, H1 2015
Neuroblastoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015
Neuroblastoma - Pipeline by Bexion Pharmaceuticals, LLC., H1 2015
Neuroblastoma - Pipeline by BioLineRx, Ltd., H1 2015
Neuroblastoma - Pipeline by Bionucleon Srl, H1 2015
Neuroblastoma - Pipeline by Cebiotex, S.L., H1 2015
Neuroblastoma - Pipeline by Celgene Corporation, H1 2015
Neuroblastoma - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015
Neuroblastoma - Pipeline by Cleveland BioLabs, Inc., H1 2015
Neuroblastoma - Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015
Neuroblastoma - Pipeline by DEKK-TEC, Inc., H1 2015
Neuroblastoma - Pipeline by Errant Gene Therapeutics, LLC, H1 2015
Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Neuroblastoma - Pipeline by Gamida Cell Ltd., H1 2015
Neuroblastoma - Pipeline by Ignyta, Inc., H1 2015
Neuroblastoma - Pipeline by Juno Therapeutics Inc., H1 2015
Neuroblastoma - Pipeline by Lindis Biotech GmbH, H1 2015
Neuroblastoma - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015
Neuroblastoma - Pipeline by Merck & Co., Inc., H1 2015
Neuroblastoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015
Neuroblastoma - Pipeline by Netris Pharma S.A.S., H1 2015
Neuroblastoma - Pipeline by Novartis AG, H1 2015
Neuroblastoma - Pipeline by Novogen Limited, H1 2015
Neuroblastoma - Pipeline by Pono Pharma, H1 2015
Neuroblastoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2015
Neuroblastoma - Pipeline by Recombio S.L, H1 2015
Neuroblastoma - Pipeline by Sareum Holdings Plc, H1 2015
Neuroblastoma - Pipeline by Shionogi & Co., Ltd., H1 2015
Neuroblastoma - Pipeline by Sutro Biopharma, Inc., H1 2015
Neuroblastoma - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Neuroblastoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015
Neuroblastoma - Pipeline by United Therapeutics Corporation, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Neuroblastoma Therapeutics - Recent Pipeline Updates, H1 2015
Neuroblastoma - Dormant Projects, H1 2015
Neuroblastoma - Dormant Projects (Contd..1), H1 2015
Neuroblastoma - Dormant Projects (Contd..2), H1 2015
Neuroblastoma - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Neuroblastoma, H1 2015
Number of Products under Development for Neuroblastoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report